Sorafenib-induced liver failure in a hepatocellular carcinoma patient: Letter to the editor

Clin Res Hepatol Gastroenterol. 2022 Jun-Jul;46(6):101931. doi: 10.1016/j.clinre.2022.101931. Epub 2022 Apr 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents* / adverse effects
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / pathology
  • Humans
  • Liver Failure*
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / pathology
  • Niacinamide / adverse effects
  • Phenylurea Compounds / adverse effects
  • Sorafenib / adverse effects

Substances

  • Antineoplastic Agents
  • Phenylurea Compounds
  • Niacinamide
  • Sorafenib